Evidence based approach for the management of mixed hyperlipidaemia.
There is now a large body of evidence from multiple clinical trials confirming that lowering plasma low density lipoprotein (LDL)-cholesterol results in a clinically significant reduction in coronary heart disease (CHD) risk. These include the Scandinavian Simvastatin Survival Study and the West of Scotland Study. However, further analyses of the Helsinki Heart Study (HHS) have provided additional detail on the relationship between other lipid changes and incidence of CHD. In the HHS, the reduction of CHD events was related not only to the LDL-cholesterol lowering ability of the drug used, but also to its HDL-cholesterol raising and triglyceride lowering effects. Furthermore, a recent comparison of the levels of atheroma regression associated with different drug classes reveals that, while statins produce much greater changes in total and LDL-cholesterol, fibrates have the most marked effect on coronary artery minimum lumen diameter changes. In practice, the overall CHD risk of patients should be reduced by a co-ordinated approach to management of all the correctable risk factors. As part of this approach, the lipid profile should be assessed and normalised initially through the instigation of lifestyle changes, and if necessary, the adjunctive use of lipid regulating drugs. While the lowering of LDL-cholesterol is clearly important, the significance of lowering plasma triglyceride should not be overlooked.